Interestingly, RAD51B and XRCC3 promoter methylation has been reported in association with the inflamed phenotype of squamous cell carcinomas of the head and neck, lung, and cervix, warranting further investigation as predictive biomarkers of response to immunotherapy [30]. This evidence concerns the gene RAD51B and squamous cell carcinoma.